CHRS实时信号 | 通过Getagraph.com最大化利润

购买 107532 min ago

@ $2.65

发出时间: 15 Feb 2024 @ 02:49

回报率: -23.02%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 0.62 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	907 176
平均成交量	2.66M
市值	231.54M
EPS	$0 ( 2024-03-13 )
下一个收益日期	( $-0.0500 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.810
ATR14	$0.00600 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Erbez Georgia	Buy	54 000	Stock Option (Right to Buy)
2024-02-20	Erbez Georgia	Buy	0
2024-02-09	Wahlstrom Mats	Buy	99 988	Common Stock
2024-02-09	Wahlstrom Mats	Sell	99 988	Common Stock
2024-02-01	Wahlstrom Mats	Buy	44 991	Common Stock

INSIDER POWER
42.69
Last 94 transactions
Buy: 4 570 164 \| Sell: 1 886 237

音量相关性

長: -0.05 (neutral)

短: -0.68 (moderate negative)

Signal:(47.66) Neutral

Coherus BioSciences Inc 相关性

10 最正相关
STRA	0.91
AVID	0.906
KPTI	0.887
EGRX	0.884
PARA	0.883
PINC	0.877
COLM	0.873
MDWD	0.868
IVAC	0.866
KTCC	0.865

10 最负相关
MORF	-0.905
RXDX	-0.901
WPRT	-0.891
IMGN	-0.882
RESN	-0.875
MDWT	-0.872
FLMN	-0.871
ACOR	-0.866
ACVA	-0.861
IDCC	-0.857

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Coherus BioSciences Inc 相关性 - 货币/商品

0.36
( neutral )

0.28
( neutral )

0.00
( neutral )

0.61
( weak )

-0.08
( neutral )

Coherus BioSciences Inc 财务报表

Annual	2023
营收:	$257.24M
毛利润:	$94.46M (36.72 %)
EPS:	$-2.53

FY	2023
营收:	$257.24M
毛利润:	$94.46M (36.72 %)
EPS:	$-2.53

FY	2022
营收:	$211.04M
毛利润:	$140.96M (66.79 %)
EPS:	$-4.21

FY	2021
营收:	$326.55M
毛利润:	$268.96M (82.36 %)
EPS:	$-3.63

Financial Reports:

No articles found.

Coherus BioSciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.